Cover Image
市場調查報告書

高三酸甘油脂血症 (hypertriglyceridemia):開發中產品分析

Hypertriglyceridemia - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 363108
出版日期 內容資訊 英文 113 Pages
訂單完成後即時交付
價格
Back to Top
高三酸甘油脂血症 (hypertriglyceridemia):開發中產品分析 Hypertriglyceridemia - Pipeline Review, H2 2016
出版日期: 2016年12月30日 內容資訊: 英文 113 Pages
簡介

本報告提供高三酸甘油脂血症 (hypertriglyceridemia) 治療藥的開發情形相關資訊,提供您各開發階段,藥物標的,作用機制,給藥途徑及分子類型別分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

高三酸甘油脂血症 (hypertriglyceridemia)的概要

治療藥的開發

  • 開發中產品的概要

高三酸甘油脂血症 (hypertriglyceridemia):企業開發中的治療藥

高三酸甘油脂血症 (hypertriglyceridemia):開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

高三酸甘油脂血症 (hypertriglyceridemia):企業開發中的產品

高三酸甘油脂血症 (hypertriglyceridemia的)治療藥的開發企業

  • AbbVie Inc.
  • Alteogen Inc.
  • Biocon Limited
  • Coherus BioSciences, Inc.
  • Epirus Biopharmaceuticals, Inc.
  • Johnson & Johnson
  • Mabion SA
  • Marathon Pharmaceuticals, LLC
  • Momenta Pharmaceuticals, Inc.
  • Mycenax Biotech Inc.
  • Novartis AG
  • Oncobiologics, Inc.
  • Oncodesign SA
  • Panacea Biotec Limited
  • Pfizer Inc.
  • Sandoz International GmbH
  • Swedish Orphan Biovitrum AB
  • Therapeutic Proteins International, LLC
  • UCB S.A.

高三酸甘油脂血症 (hypertriglyceridemia):治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

高三酸甘油脂血症 (hypertriglyceridemia):暫停中的計劃

高三酸甘油脂血症 (hypertriglyceridemia):中止開發的產品

高三酸甘油脂血症 (hypertriglyceridemia):產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8852IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypertriglyceridemia - Pipeline Review, H2 2016, provides an overview of the Hypertriglyceridemia (Metabolic Disorders) pipeline landscape.

Hypertriglyceridemia is a condition in which triglyceride levels are elevated. Causes include diabetes mellitus, obesity, family history and sedentary habits. Symptoms include gastrointestinal pain, difficulty breathing, memory loss, dementia, xanthelasmas and corneal arcus. Treatment includes diuretics, beta-blockers, estrogen therapy and corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypertriglyceridemia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hypertriglyceridemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypertriglyceridemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypertriglyceridemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 9, 1, 2, 11 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Hypertriglyceridemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hypertriglyceridemia (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hypertriglyceridemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hypertriglyceridemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hypertriglyceridemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hypertriglyceridemia (Metabolic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hypertriglyceridemia (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hypertriglyceridemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hypertriglyceridemia Overview
  • Therapeutics Development
    • Pipeline Products for Hypertriglyceridemia - Overview
    • Pipeline Products for Hypertriglyceridemia - Comparative Analysis
  • Hypertriglyceridemia - Therapeutics under Development by Companies
  • Hypertriglyceridemia - Therapeutics under Investigation by Universities/Institutes
  • Hypertriglyceridemia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Hypertriglyceridemia - Products under Development by Companies
  • Hypertriglyceridemia - Products under Investigation by Universities/Institutes
  • Hypertriglyceridemia - Companies Involved in Therapeutics Development
    • Acasti Pharma Inc
    • Akcea Therapeutics Inc
    • Allergan Plc
    • Alnylam Pharmaceuticals Inc
    • Arisaph Pharmaceuticals Inc
    • AstraZeneca Plc
    • BASF SE
    • Cardax Inc
    • Catabasis Pharmaceuticals Inc
    • Celon Pharma SA
    • CymaBay Therapeutics Inc
    • Gemphire Therapeutics Inc
    • Jeil Pharmaceutical Co Ltd
    • Kyorin Pharmaceutical Co Ltd
    • LipimetiX Development Inc
    • Matinas BioPharma Holdings Inc
    • Sancilio & Company Inc
    • Zydus Cadila Healthcare Ltd
  • Hypertriglyceridemia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AEM-28 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AEM-2814 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ALN-AC3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ALN-ANG - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antibody to Inhibit ANGPTL4 for Hypertriglyceridemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARI-3037MO - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bezafibrate SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BioE-1115 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BSN-272 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CAT-2000 Series - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CAT-2003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CDX-085 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • gemcabene calcium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • icosabutate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IONIS-ANGPTL3LRx - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IONIS-APOCIIILRX - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LTPO-3FA - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MAT-9001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MN-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NKPL-66 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • omega-3-carboxylic acids - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • saroglitazar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SC-401 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • seladelpar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Hypertriglyceridaemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides for Dyslipidemic and Vascular Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • volanesorsen sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Hypertriglyceridemia - Dormant Projects
  • Hypertriglyceridemia - Discontinued Products
  • Hypertriglyceridemia - Product Development Milestones
    • Featured News & Press Releases
      • Dec 19, 2016: Akcea and Ionis Announce Positive Results from COMPASS Phase 3 Study of Volanesorsen
      • Sep 14, 2016: Acasti Pharma Reports Positive CaPre Omega-3 Bridging Study Data
      • Jun 11, 2016: New Scientific Data of Investigational Lipaglyn (Saroglitazar), and Real World Data in Patients will be Featured at American Diabetes Association (ADA) 76th Scientific Sessions
      • May 16, 2016: Akcea Therapeutics Announces Completion of Enrollment in Phase 3 COMPASS Trial of Volanesorsen
      • Mar 23, 2016: MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia
      • Feb 24, 2016: SPCI Announces US PTO Allowance of Patent Claims
      • Nov 18, 2015: Zydus announces clinical trials of Saroglitazar in patients with Severe Hypertriglyceridemia in USA
      • Jul 29, 2015: Positive Clinical Data From Volanesorsen Published in the New England Journal of Medicine
      • May 25, 2015: Phase 2a Clinical Study of Icosabutate in Patients with Severe Hypertriglyceridemia
      • Apr 22, 2015: CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 in Severe Hypertriglyceridemia
      • Mar 02, 2015: Acasti Receives Full Data for Phase II TRIFECTA Trial
      • Sep 30, 2014: Acasti Announces Positive Top-Line Pharmacokinetic Results
      • Sep 29, 2014: Acasti Reports Successful CaPre Phase II TRIFECTA Results Proving Statistically Significant Improvements in Triglycerides & Non-HDL-C
      • Sep 02, 2014: Isis Pharmaceuticals Presents Data On ISIS-APOCIIIRX At European Society of Cardiology Congress 2014
      • Jul 24, 2014: Acasti Announces Oral Presentation on COLT Study Results at 19th World Congress on Heart Disease in Boston
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Hypertriglyceridemia, H2 2016
  • Number of Products under Development for Hypertriglyceridemia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Hypertriglyceridemia - Pipeline by Acasti Pharma Inc, H2 2016
  • Hypertriglyceridemia - Pipeline by Akcea Therapeutics Inc, H2 2016
  • Hypertriglyceridemia - Pipeline by Allergan Plc, H2 2016
  • Hypertriglyceridemia - Pipeline by Alnylam Pharmaceuticals Inc, H2 2016
  • Hypertriglyceridemia - Pipeline by Arisaph Pharmaceuticals Inc, H2 2016
  • Hypertriglyceridemia - Pipeline by AstraZeneca Plc, H2 2016
  • Hypertriglyceridemia - Pipeline by BASF SE, H2 2016
  • Hypertriglyceridemia - Pipeline by Cardax Inc, H2 2016
  • Hypertriglyceridemia - Pipeline by Catabasis Pharmaceuticals Inc, H2 2016
  • Hypertriglyceridemia - Pipeline by Celon Pharma SA, H2 2016
  • Hypertriglyceridemia - Pipeline by CymaBay Therapeutics Inc, H2 2016
  • Hypertriglyceridemia - Pipeline by Gemphire Therapeutics Inc, H2 2016
  • Hypertriglyceridemia - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2016
  • Hypertriglyceridemia - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2016
  • Hypertriglyceridemia - Pipeline by LipimetiX Development Inc, H2 2016
  • Hypertriglyceridemia - Pipeline by Matinas BioPharma Holdings Inc, H2 2016
  • Hypertriglyceridemia - Pipeline by Sancilio & Company Inc, H2 2016
  • Hypertriglyceridemia - Pipeline by Zydus Cadila Healthcare Ltd, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Hypertriglyceridemia - Dormant Projects, H2 2016
  • Hypertriglyceridemia - Dormant Projects (Contd..1), H2 2016
  • Hypertriglyceridemia - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Hypertriglyceridemia, H2 2016
  • Number of Products under Development for Hypertriglyceridemia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top